A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results